This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesDisease AwarenessDisease AwarenessAspergillosisOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseINSPIRE To: Change the Course Season 2The global threat of carbapenemase-producing enterobacterales (CPE)CPE Epidemiology CPE Factsheet London AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Online Learning
INSPIRE To: Change the Course

The management of invasive aspergillosis (IA) in an ICU setting

Lisa Nwankwo | Specialist Pharmacist, Antimicrobials | Royal Brompton and Harefield Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust

In this 2-part series, Lisa Nwankwo:

  • Discusses the key considerations in selection of antifungal therapy and management of patient populations of interest.
  • Presents a real-world case study of a patient with IA treated with isavuconazole.
At the end of the course, you will be able to download a certificate of completion.


Lisa Nwankwo is a Specialist Pharmacist, Antimicrobials at the Royal Brompton and Harefield Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust.

 

Considerations for selecting antifungal treatment

Lisa Nwankwo explores the pharmaceutical management of IA in the ICU, including how different patient and pathogenic factors may influence selection of antifungal therapies.

Learning objectives & questions to consider
Learning Objectives:
  • Understand how patient-specific factors, such as weight, renal function, hepatic impairment, and concomitant medication, impact antifungal treatment decisions
  • Recognise the importance of TDM in optimising antifungal therapy
  • Be aware of the considerations for special populations including pregnant patients and children in the context of antifungal treatment
Questions to consider:
  • How does patient weight affect the selection of antifungal therapy, and why might dose capping be necessary in some cases?
  • What are the key considerations related to renal function and renal impairment when using antifungal medications?
  • What precautions/measures need to be considered when treating paediatric or 
pregnant patients for example?

 

Case study: Treatment of IA with isavuconazole

Lisa Nwankwo takes you through a patient case study from presentation to diagnosis 
and treatment.

Questions to consider
  • Which imaging tests would you carry out on this patient?
  • What would be your treatment considerations for this patient in the pre-ICU setting?
  • How would the patient’s renal comorbidities influence your choice of treatment?
  • How would you manage/follow up with this patient following discharge?
Certificate Download

Download a certificate to demonstrate your completion of the Lisa Nwankwo video Series: The management of invasive aspergillosis (IA) in an ICU setting

DownloadLoading
Learn More - Dr Hasti Robbie & Claire Berry Click here to go to a two part series on Radiological & Laboratory Diagnostic approaches for Invasive Fungal Infections (IFIs)Go to module 2Loading
CRESEMBA® 
(isavuconazole)

CRESEMBA® (isavuconazole) is indicated in adults for the treatment of Invasive Aspergillosis and also for the treatment of Mucormycosis in patients for whom amphotericin B is inappropriate.

Consideration should be given to official guidance on the appropriate use of antifungal agents.

Learn more
Loading

IA, invasive aspergillosis; ICU, intensive care unit; TDM, therapeutic drug monitoring.

Prescribing Information:

Click here for Prescribing Information for CRESEMBA® (isavuconazole) and Vfend (voriconazole)

PP-CRB-GBR-2502. June 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​